EE382 Cost-Utility Analysis of Avacopan for the Treatment of Anca-Associated Vasculitis (AAV) Patients in the UK
AR de Arellano Serna, V Berdunov… - Value in …, 2022 - valueinhealthjournal.com
Objectives The objective of this study was to evaluate the cost-utility of avacopan in
combination with cyclophosphamide or rituximab compared with glucocorticoids (GC) and
cyclophosphamide or rituximab for patients with anti-neutrophil cytoplasmic antibody
(ANCA)–associated vasculitis (AAV) in the UK National Health Service (NHS). Methods A
state-transition Markov model was designed to reflect clinical practice for induction of
remission in patients with ANCA-associated vasculitis, with up to three induction courses …
combination with cyclophosphamide or rituximab compared with glucocorticoids (GC) and
cyclophosphamide or rituximab for patients with anti-neutrophil cytoplasmic antibody
(ANCA)–associated vasculitis (AAV) in the UK National Health Service (NHS). Methods A
state-transition Markov model was designed to reflect clinical practice for induction of
remission in patients with ANCA-associated vasculitis, with up to three induction courses …
以上显示的是最相近的搜索结果。 查看全部搜索结果